Connection

Mark Rubinstein to Proteins

This is a "connection" page, showing publications Mark Rubinstein has written about Proteins.
Connection Strength

0.663
  1. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704.
    View in: PubMed
    Score: 0.473
  2. A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses. J Biol Chem. 2016 Nov 11; 291(46):23869-23881.
    View in: PubMed
    Score: 0.106
  3. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor aSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 2013 May 15; 73(10):3075-86.
    View in: PubMed
    Score: 0.084
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.